Radium-223 for the treatment of bone metastasis of prostate cancer / 中华男科学杂志
National Journal of Andrology
;
(12): 78-81, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-812805
ABSTRACT
Over 80% of the patients with prostate cancer (PCa) develop bone metastasis, which seriously affects the patients' quality of life and remains a major cause of morbidity. Radium-223 (Ra-223), a newly approved agent targeting bone metastasis of PCa, can improve the quality of life and prolong the overall survival of the PCa patients with bone metastasis. This article presents an overview of the clinical trials recently published on the management of bone metastasis of PCa with Ra-223.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Pathology
/
Prostatic Neoplasms
/
Quality of Life
/
Radioisotopes
/
Radiotherapy
/
Bone Neoplasms
/
Clinical Trials as Topic
/
Radium
/
Therapeutic Uses
Limits:
Humans
/
Male
Language:
Chinese
Journal:
National Journal of Andrology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS